Short Interest in LivaNova PLC (NASDAQ:LIVN) Declines By 18.6%

LivaNova PLC (NASDAQ:LIVN) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 1,580,000 shares, a drop of 18.6% from the February 13th total of 1,940,000 shares. Based on an average daily volume of 613,400 shares, the short-interest ratio is presently 2.6 days. Currently, 2.9% of the shares of the stock are sold short.

LivaNova Stock Down 0.7 %

LIVN stock traded down $0.30 during midday trading on Thursday, hitting $40.54. The company’s stock had a trading volume of 217,148 shares, compared to its average volume of 600,006. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company’s fifty day moving average price is $45.60 and its 200 day moving average price is $48.89. The stock has a market capitalization of $2.20 billion, a P/E ratio of 96.67 and a beta of 1.10. LivaNova has a twelve month low of $36.85 and a twelve month high of $64.48.

Hedge Funds Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its position in shares of LivaNova by 22.2% in the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after acquiring an additional 12,470 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in LivaNova in the 4th quarter valued at about $1,954,000. KBC Group NV grew its holdings in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after purchasing an additional 56,580 shares during the period. Rhumbline Advisers grew its holdings in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after purchasing an additional 899 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after buying an additional 93,311 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on LIVN. The Goldman Sachs Group reduced their price objective on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research note on Monday. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Barclays dropped their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.